Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
Clinical trial NCT04287894 · TERMINATED
Trial details
- NCT number
- NCT04287894
- Sponsor
- The Netherlands Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-28
- Primary completion
- 2024-11-04
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.